Insider · CIK 0001398940

MOLINA ARTURO MD

Reports to the SEC for 4 companies · NEWARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001398940

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-26	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−15K sh	—	—	50,971
2026-03-26	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+15K sh	$8.04	+$121K	99,115
2026-03-26	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−15K sh	$104.79	−$1.57M	84,115
2026-01-27	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−5,000 sh	—	—	65,971
2026-01-27	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−5,000 sh	$82.00	−$410K	84,115
2026-01-27	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+5,000 sh	$8.04	+$40.2K	89,115
2026-01-26	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+5,000 sh	$8.04	+$40.2K	89,115
2026-01-26	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−5,000 sh	$82.28	−$411K	84,115
2026-01-26	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−5,000 sh	—	—	70,971
2026-01-23	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−13.2K sh	$82.42	−$1.08M	84,115
2026-01-20	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−9,514 sh	$82.48	−$785K	97,266
2026-01-02	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Medical Officer	AAward	+32K sh	—	—	32,000
2026-01-02	PTGXProtagonist Therapeutics, IncA Award	Chief Medical Officer	AAward	+25.6K sh	—	—	106,780
2025-11-17	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−2,712 sh	$84.77	−$230K	81,180
2025-06-10	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−10K sh	—	—	75,971
2025-06-10	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−10K sh	$57.03	−$570K	83,892
2025-06-10	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+10K sh	$8.04	+$80.4K	93,892
2025-06-09	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+10K sh	$8.04	+$80.4K	93,892
2025-06-09	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−10K sh	$55.51	−$555K	83,892
2025-06-09	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−10K sh	—	—	85,971
2025-03-13	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−2,077 sh	—	—	47,785
2025-03-13	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−28.4K sh	—	—	69,063
2025-03-13	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−30.5K sh	$55.74	−$1.7M	83,892
2025-03-13	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+2,077 sh	$38.98	+$81K	114,406
2025-03-13	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+28.4K sh	$23.42	+$666K	112,329
2025-01-16	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−388 sh	—	—	87,144
2025-01-16	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−3,252 sh	—	—	83,892
2025-01-02	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Medical Officer	AAward	+49.9K sh	—	—	49,862
2025-01-02	PTGXProtagonist Therapeutics, IncA Award	Chief Medical Officer	AAward	+41.1K sh	—	—	87,532
2024-11-27	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−10K sh	$44.50	−$445K	46,444
2024-11-27	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−10K sh	—	—	111,971
2024-11-27	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−16K sh	—	—	95,971
2024-11-27	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+10K sh	$8.04	+$80.4K	56,444
2024-11-27	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+16K sh	$8.04	+$129K	62,444
2024-11-27	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−16K sh	$44.83	−$717K	46,444
2024-11-26	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−5,529 sh	$45.60	−$252K	46,444
2024-11-26	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−5,529 sh	—	—	121,971
2024-11-26	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+5,529 sh	$8.04	+$44.5K	51,973
2024-11-15	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−1,906 sh	$40.98	−$78.1K	46,444
2024-01-16	PTGXProtagonist Therapeutics, IncF Tax Payment	Chief Medical Officer	FTax Payment	−427 sh	$24.63	−$10.5K	48,350
2024-01-02	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Medical Officer	AAward	+97.5K sh	—	—	97,500
2024-01-02	PTGXProtagonist Therapeutics, IncA Award	Chief Medical Officer	AAward	+26.3K sh	—	—	48,777
2023-11-15	PTGXProtagonist Therapeutics, IncS Sale	Chief Medical Officer	SSale	−1,848 sh	$16.24	−$30K	22,527
2023-01-16	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Medical Officer	AAward	+18.8K sh	—	—	18,750
2023-01-16	PTGXProtagonist Therapeutics, IncA Award	Chief Medical Officer	AAward	+3,125 sh	—	—	24,375
2022-11-15	PTGXProtagonist Therapeutics, IncA Award	Chief Medical Officer	AAward	+21.3K sh	—	—	21,250
2022-11-15	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Medical Officer	AAward	+128K sh	—	—	127,500
2022-10-14	Forma Therapeutics Holdings, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−16.8K sh	—	—	0
2022-10-14	Forma Therapeutics Holdings, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,750 sh	—	—	0
2022-10-14	Forma Therapeutics Holdings, Inc.U Disposition from Tender	Director	UDisposition from Tender	−10K sh	—	—	0

Recent filings

Accepted (ET)
Mar 274
MOLINA ARTURO MD0001104659-26-036319
SEC(opens sec.gov)
Jan 274
MOLINA ARTURO MD0001104659-26-007127
SEC(opens sec.gov)
Jan 214
MOLINA ARTURO MD0001104659-26-005443
SEC(opens sec.gov)
Jan 64
MOLINA ARTURO MD0001104659-26-001471
SEC(opens sec.gov)
Nov 194
MOLINA ARTURO MD0001104659-25-114082
SEC(opens sec.gov)
Jun 114
MOLINA ARTURO MD0001104659-25-058597
SEC(opens sec.gov)

Companies

Address

C/O PROTAGONIST THERAPEUTICS, INC. 7707 GATEWAY BLVD., SUITE 140

NEWARK, CA, 94560-1160